Chemomab Therapeutics Ltd expected to post a loss of 10  cents a share - Earnings Preview

Chemomab Therapeutics

07/03/2022 11:15

* Chemomab Therapeutics Ltd  CMMB.OQ   CMMB.O  is expected
to report results on March 9.
    * ​Refinitiv's mean analyst estimate for Chemomab
Therapeutics Ltd
is for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $30​, about 86.7% above​ its last closing
price of $3.98. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021              -0.14      -0.26     Missed  -79.3
 Jun. 30 2021  -0.10       -0.11      -0.26     Missed  -126.1
 Mar. 31 2021  -0.43       -0.43      -0.22     Beat    48.8​
 ​​                                                     
                                                        ​
 Mar. 31 2020  -1.76       -1.84      -8.00     Missed  -334.8
 Dec. 31 2019  -2.00       -2.00      31.20     Beat    1,660
 This summary was machine generated March 7 at 11:15 GMT.  All
figures in US dollars  unless otherwise stated